Literature DB >> 27993578

"Sarcomatoid" carcinomas of the lung: a clinicopathological study of 86 cases with a new perspective on tumor classification.

Annikka Weissferdt1, Neda Kalhor2, Arlene M Correa3, Cesar A Moran2.   

Abstract

Pulmonary sarcomatoid carcinoma includes a heterogenous group of tumors difficult to diagnose and treat. We report the clinicopathological features of 86 such tumors, including 74 pleomorphic and 12 spindle cell carcinomas, and propose a novel approach to the classification of these neoplasms in an attempt to better guide patient management. The patients were 47 men and 39 women aged 36 to 87 years (mean, 63 years) who primarily presented with shortness of breath, cough, and chest pain. Eighty-six percent of patients had a smoking history. Histologically, the pleomorphic carcinomas consisted of spindle and/or giant cells with varying proportions of conventional non-small cell carcinoma in the form of adenocarcinoma (n=29), squamous cell carcinoma (n=10), or large cell carcinoma (n=18); 17 cases contained a mix of spindle and giant cells only. The 12 spindle cell carcinomas consisted of spindle cells only. Based on the combined histopathologic and immunohistochemical features of these tumors, we were able to reanalyze the spectrum of these lesions and reclassify them accordingly. Statistical analysis revealed an overall survival at 3, 5, and 10 years of 42.9%, 34.6%, and 23.5%, respectively, and a median survival of 15 months. Log-rank test showed that in multivariate analysis, only pathological T stage was a factor associated with prognosis. The current classification of pulmonary sarcomatoid carcinomas precludes optimal triaging of these tumors with the risk of denying patients access to novel treatment. Our proposal for a reclassification of these tumors would more accurately guide patient management and facilitate targeted therapies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; Immunohistochemistry; Lung; Non–small cell carcinoma; Pleomorphic carcinoma; Sarcomatoid carcinoma; Spindle cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27993578     DOI: 10.1016/j.humpath.2016.12.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.

Authors:  Xuewen Liu; Fang Wang; Chunwei Xu; Xinru Chen; Xue Hou; Qian Li; Pansong Li; Zhi Xie; Yongdong Liu; Lianpeng Chang; Yanfang Guan; Xuchao Zhang; Ling Yang; Hui Wang; Xin Yi; Jianjun Zhang; Xuefeng Xia; Cesar Moran; Likun Chen
Journal:  Oncogene       Date:  2020-12-03       Impact factor: 9.867

2.  Additional chemotherapy improves survival in stage II-III pulmonary sarcomatoid carcinoma patients undergoing surgery: a propensity scoring matching analysis.

Authors:  Yanhong Cen; Chunxu Yang; Jiangbo Ren; Yan Gong; Conghua Xie
Journal:  Ann Transl Med       Date:  2021-01

3.  Clinicopathological features and prognostic analysis of metastatic pulmonary sarcomatoid carcinoma: a SEER analysis.

Authors:  Congjia Xiao; Xudong Yang; Jianqi Hao; Chenglin Guo; Qiang Pu; Lunxu Liu
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

4.  Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.

Authors:  Ziwei Liang; Enyu Zhang; Ling Duan; Nathaniel Weygant; Guangyu An; Bin Hu; Jiannan Yao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma.

Authors:  Sara Lázaro; Corina Lorz; Ana Belén Enguita; Iván Seller; Jesús M Paramio; Mirentxu Santos
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

6.  Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre.

Authors:  Suresh Kumar Bondili; Ravindra Nandhana; Aditya Dhanawat; Vanita Noronha; Amit Joshi; Vijay Maruti Patil; Nandini Menon; Rajiv Kumar Kaushal; Anuradha Choughule; Sabita S Jiwnani; Amit Janu; Kumar Prabhash
Journal:  Ecancermedicalscience       Date:  2022-08-08

7.  Development and validation of a prognostic predictive model of pulmonary spindle cell carcinoma from the surveillance, epidemiology and end results database.

Authors:  Wei Li; Minghang Zhang; Siyun Fu; Xuefeng Hao; Liwei Song; Jinghui Wang; Bin Liu; Shaofa Xu
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

8.  Adjuvant chemotherapy is not a decisive factor in improving the overall survival of pulmonary sarcoma: A population-based study.

Authors:  Long Liang; Zixuan Liu; Changhui Wang; Shuanshuan Xie
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

9.  Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas.

Authors:  Greta Alì; Rossella Bruno; Anello Marcello Poma; Ornella Affinito; Antonella Monticelli; Paolo Piaggi; Sara Ricciardi; Marco Lucchi; Franca Melfi; Antonio Chella; Sergio Cocozza; Gabriella Fontanini
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

10.  A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.

Authors:  Kosuke Sawatari; Motohiro Izumi; Risa Sone; Tsuyoshi Hattori; Akira Sugimoto; Yosuke Eguchi; Takashi Mamoto
Journal:  Respir Med Case Rep       Date:  2022-01-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.